公衆衛生86巻10号

2022年10月発行

特集 認知症施策up to date

認知症の血液バイオマーカーへの期待と課題

著者： 池内健¹

所属機関： ¹新潟大学脳研究所生命科学リソース研究センター

ページ範囲：P.842 - P.850

ポイント
◆認知症の新しい診断ツールとして、脳内病理変化を反映する血液バイオマーカーの開発が進んでいる。
◆汎用性が高い血液バイオマーカーは、認知症診療の枠組みを変革する可能性がある。
◆認知症の血液バイオマーカーは、倫理面に配慮しながら適正に使用することが望まれる。

参考文献

1）Olsson B, et al: CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 15: 673-684, 2016

2）Nakamura A, et al: High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature 554: 249-254, 2018

test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clin Chim Acta 519: 267-275, 2021

4）Teunissen CE, et al: Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol 21: 66-77, 2022

5）Palmqvist S, et al: Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. JAMA Neurol 76: 1060-1069, 2019

6）Janelidze S, et al: Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. JAMA Neurol 78: 1375-1382, 2021

7）Pannee J, et al: The global Alzheimer's Association round robin study on plasma amyloid β methods. Alzheimers Dement（Amst）13: e12242, 2021

8）Tatebe H, et al: Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome. Mol Neurodegener 12: 63, 2017

9）Karikari TK, et al: Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19: 422-433, 2020

10）Sato C, et al: Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 98: 861-864, 2018

11）Palmqvist S, et al: Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 324: 772-781, 2020

12）Mattsson-Carlgren N, et al: Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain 143: 3234-3241, 2020

13）Palmqvist S, et al: Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med 27: 1034-1042, 2021

14）Gafson AR, et al: Neurofilaments: neurobiological foundations for biomarker applications. Brain 143: 1975-1998, 2020

15）Khalil M, et al: Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14: 577-589, 2018

16）Gaetani L et al: Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90: 870-881, 2019

17）Bridel C, et al: Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol 76: 1035-1048, 2019

18）Darras BT, et al: Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol 6: 932-944, 2019

19）Garwood C J, et al: Review: Astrocytes in Alzheimer's disease and other age-associated dementias: a supporting player with a central role. Neuropathol Appl Neurobiol 43: 281-298, 2017

20）Verberk IMW, et al: Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev 2: E87-E95, 2021

21）Asken BM, et al: Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage. J Alzheimers Dis 78: 265-276, 2020

22）Cicognola C, et al: Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther 13: 68, 2021

23）Elahi FM, et al: Plasma biomarkers of astrocytic and neuronal dysfunction in early-and late-onset Alzheimer's disease. Alzheimers Dement 16: 681-695, 2020

24）Heller C, et al: Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J Neurol Neurosurg Psychiatry 91: 263-270, 2020

25）Oeckl P, et al: Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. J Alzheimers Dis 67: 481-488, 2019

26）認知症性疾患診療ガイドライン作成委員会（編）：認知症疾患診療ガイドライン2017．医学書院，2017

27）厚生労働省科学研究費研究班：認知症に関する脳脊髄液・血液バイオマーカーの適正使用指針．2021年3月31日　https://square.umin.ac.jp/dementia/pdf/biomarker_guideline.pdf（2022年7月20日閲覧）

28）日本核医学会，他（編）：アミロイドPETイメージング剤の適正使用ガイドライン（第2版）．2017年11月17日　http://jsnm.org/wp_jsnm/wp-content/themes/theme_jsnm/doc/amyloid_pet_imaging_gl_2.pdf（2022年7月20日閲覧）

29）Erickson CM, et al: Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know. Alzheimers Dement（Amst）13: e12150, 2021

30）Frisoni GB, et al: Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurol 16: 661-676, 2017